Paper39720556
Recent advances in the treatment of non-small cell lung cancer with MET inhibitors.
Zhang D and 7 others. Front Chem, 2024. Cited by 4 papers, by iCite.
Cite this record
ConductScience Library. Recent advances in the treatment of non-small cell lung cancer with MET inhibitors. Papers, record 39720556. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/39720556
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
References104
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 38572751 | Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. | CA Cancer J Clin | 2024 | https://conductscience.org/library/papers/38572751 | PubMed |
| 2 | 23944843 | Lessons from (S)-6-(1-(6-(1-methyl-1H-pyrazol-4-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl)ethyl)quinoline (PF-04254644), an inhibitor of receptor tyrosine kinase c-Met with high protein kinase selectivity but broad phosphodiesterase family inhibition leading to myocardial degeneration in rats. | J Med Chem | 2013 | https://conductscience.org/library/papers/23944843 | PubMed |
| 3 | 32034073 | Molecular Mechanisms of Acquired Resistance to MET Tyrosine Kinase Inhibitors in Patients with MET Exon 14-Mutant NSCLC. | Clin Cancer Res | 2020 | https://conductscience.org/library/papers/32034073 | PubMed |
| 4 | 38074469 | Structural insight into the macrocyclic inhibitor TPX-0022 of c-Met and c-Src. | Comput Struct Biotechnol J | 2023 | https://conductscience.org/library/papers/38074469 | PubMed |
| 5 | 34076436 | Synthetic Opportunities and Challenges for Macrocyclic Kinase Inhibitors. | J Med Chem | 2021 | https://conductscience.org/library/papers/34076436 | PubMed |
| 6 | 34391508 | Treatment-related adverse events of PD-1 and PD-L1 inhibitor-based combination therapies in clinical trials: a systematic review and meta-analysis. | Lancet Oncol | 2021 | https://conductscience.org/library/papers/34391508 | PubMed |
| 7 | 33666419 | Structure-Based Design of High-Affinity Macrocyclic FKBP51 Inhibitors. | J Med Chem | 2021 | https://conductscience.org/library/papers/33666419 | PubMed |
| 8 | 34804015 | Selective Inhibitor of the c-Met Receptor Tyrosine Kinase in Advanced Hepatocellular Carcinoma: No Beneficial Effect With the Use of Tivantinib? | Front Immunol | 2021 | https://conductscience.org/library/papers/34804015 | PubMed |
| 9 | 29157685 | Recent advances in the discovery of small molecule c-Met Kinase inhibitors. | Eur J Med Chem | 2018 | https://conductscience.org/library/papers/29157685 | PubMed |
| 10 | 36843841 | Tivantinib alleviates inflammatory diseases by directly targeting NLRP3. | iScience | 2023 | https://conductscience.org/library/papers/36843841 | PubMed |
| 11 | 38239394 | Mechanisms of tyrosine kinase inhibitor resistance in renal cell carcinoma. | Cancer Drug Resist | 2023 | https://conductscience.org/library/papers/38239394 | PubMed |
| 12 | 30909397 | C-Met as a Key Factor Responsible for Sustaining Undifferentiated Phenotype and Therapy Resistance in Renal Carcinomas. | Cells | 2019 | https://conductscience.org/library/papers/30909397 | PubMed |
| 13 | 38430418 | MET overexpression correlated with prognosis of EGFR-mutant treatment‑naïve advanced lung adenocarcinoma: a real‑world retrospective study. | Clin Transl Oncol | 2024 | https://conductscience.org/library/papers/38430418 | PubMed |
| 14 | 32432477 | Medicinal Chemistry Strategies for the Development of Kinase Inhibitors Targeting Point Mutations. | J Med Chem | 2020 | https://conductscience.org/library/papers/32432477 | PubMed |
| 15 | 34663410 | Resistance to anti-EGFR therapies in metastatic colorectal cancer: underlying mechanisms and reversal strategies. | J Exp Clin Cancer Res | 2021 | https://conductscience.org/library/papers/34663410 | PubMed |
| 16 | 32479794 | Tepotinib plus gefitinib in patients with EGFR-mutant non-small-cell lung cancer with MET overexpression or MET amplification and acquired resistance to previous EGFR inhibitor (INSIGHT study): an open-label, phase 1b/2, multicentre, randomised trial. | Lancet Respir Med | 2020 | https://conductscience.org/library/papers/32479794 | PubMed |
| 17 | 16052207 | Hepatocyte growth factor promotes lymphatic vessel formation and function. | EMBO J | 2005 | https://conductscience.org/library/papers/16052207 | PubMed |
| 18 | 29990309 | Hgf/Met activation mediates resistance to BRAF inhibition in murine anaplastic thyroid cancers. | J Clin Invest | 2018 | https://conductscience.org/library/papers/29990309 | PubMed |
| 19 | 38386085 | MET receptor serves as a promising target in melanoma brain metastases. | Acta Neuropathol | 2024 | https://conductscience.org/library/papers/38386085 | PubMed |
| 20 | 31227004 | MET inhibitors for targeted therapy of EGFR TKI-resistant lung cancer. | J Hematol Oncol | 2019 | https://conductscience.org/library/papers/31227004 | PubMed |
Cited by3
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 4 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42597321 | MAML-residual transformer for few-shot prediction of targeted therapy response in NSCLC. | Front Cell Dev Biol | 2026 | https://conductscience.org/library/papers/42597321 | PubMed |
| 40641110 | MicroRNA‑21: A potential therapeutic target in lung cancer (Review). | Int J Oncol | 2025 | https://conductscience.org/library/papers/40641110 | PubMed |
| 40289194 | The role of Wnt/β-catenin signaling in lung cancer progression and therapy: a comprehensive review. | Med Oncol | 2025 | https://conductscience.org/library/papers/40289194 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/39720556
GET https://conductscience.org/api/papers/v1/39720556/references?page=2